Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey J Roszkowski

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Translational Medicine|September 22, 2005
T cell avidity and tumor recognition: implications and therapeutic strategiesMark D McKee, Jeffrey J Roszkowski, Michael I Nishimura
Cancer Research|December 6, 2006
Influence of human CD8 on antigen recognition by T-cell receptor-transduced cellsGretchen E Lyons, Tamson Moore, Natasha Brasic, et al.
Cancer Immunology, Immunotherapy : CII|December 24, 2005
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cellsGretchen E Lyons, Jeffrey J Roszkowski, Stephen Man, et al.
Cancer Research|March 1, 2005
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptorJeffrey J Roszkowski, Gretchen E Lyons, W Martin Kast, et al.
Cancer Treatment and Research|October 11, 2005
Antigen recognition and T-cell biologyMichael I Nishimura, Jeffrey J Roszkowski, Tamson V Moore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 21, 2003
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cellJeffrey J Roszkowski, David C Yu, Mark P Rubinstein, et al.
Hepatology (Baltimore, Md.)|April 22, 2006
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognitionGlenda G Callender, Hugo R Rosen, Jeffrey J Roszkowski, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognitionTamson V Moore, Gretchen E Lyons, Natasha Brasic, et al.
Cancer Immunology, Immunotherapy : CII|January 7, 2010
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targetingHåkan Norell, Yi Zhang, James McCracken, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2016
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsTimothy T Spear, Glenda G Callender, Jeffrey J Roszkowski, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Translational Medicine|September 22, 2005
T cell avidity and tumor recognition: implications and therapeutic strategiesMark D McKee, Jeffrey J Roszkowski, Michael I Nishimura
Cancer Research|December 6, 2006
Influence of human CD8 on antigen recognition by T-cell receptor-transduced cellsGretchen E Lyons, Tamson Moore, Natasha Brasic, et al.
Cancer Immunology, Immunotherapy : CII|December 24, 2005
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cellsGretchen E Lyons, Jeffrey J Roszkowski, Stephen Man, et al.
Cancer Research|March 1, 2005
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptorJeffrey J Roszkowski, Gretchen E Lyons, W Martin Kast, et al.
Cancer Treatment and Research|October 11, 2005
Antigen recognition and T-cell biologyMichael I Nishimura, Jeffrey J Roszkowski, Tamson V Moore, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 21, 2003
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cellJeffrey J Roszkowski, David C Yu, Mark P Rubinstein, et al.
Hepatology (Baltimore, Md.)|April 22, 2006
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognitionGlenda G Callender, Hugo R Rosen, Jeffrey J Roszkowski, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2008
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognitionTamson V Moore, Gretchen E Lyons, Natasha Brasic, et al.
Cancer Immunology, Immunotherapy : CII|January 7, 2010
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targetingHåkan Norell, Yi Zhang, James McCracken, et al.
Cancer Immunology, Immunotherapy : CII|February 5, 2016
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumorsTimothy T Spear, Glenda G Callender, Jeffrey J Roszkowski, et al.
Pageof 2